Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247972 · ClinicalTrials.gov registry record
Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease
A clinical trial, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- 30
- Enrollment target
NCT03247972 is a clinical trial that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 30 participants.
The verdict
NCT03247972 was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This investigation will be conducted in subjects \>18 years of age with PAD. Platelet activation and aggregation, and biomarkers associated with platelet activation, oxidative stress, and inflammation will be assessed prior to initiation of study-HD statin therapy (baseline), after 8 weeks of high-dose statins and 24 hours and 8 weeks after high dose statin + evolocumab therapy
Interventions
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-08-11 |
| Est. Completion | 2019-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03247972
The ClinicalTrials.gov registry entry for NCT03247972 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evolocumab is the first listed.
NCT03247972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03247972 about?
NCT03247972 is a clinical study titled "Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease". This investigation will be conducted in subjects \>18 years of age with PAD. Platelet activation and aggregation, and biomarkers associated with platelet activation, oxidative stress, and inflammation will be assessed prior to initiation of study-HD statin therapy (baseline), after 8 weeks of high-d...
What is the current status of trial NCT03247972?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2017-08-11. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03247972?
The interventions under investigation include: Evolocumab (DRUG).
Who is sponsoring clinical trial NCT03247972?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.